(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 November 2010 (11.11.2010)

PCT

(10) International Publication Number
WO 2010/129503 A1

(51) International Patent Classification:
A61K 38/18 (2006.01) *C07K 14/50* (2006.01)

(21) International Application Number:
PCT/US2010/033478

(22) International Filing Date:
4 May 2010 (04.05.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/175,736 5 May 2009 (05.05.2009) US
61/285,118 9 December 2009 (09.12.2009) US

(71) Applicant *(for all designated States except US)*: **AMGEN INC.** [US/US]; One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BELOUSKI, Edward John** [US/US]; 4541 La Tuna Court, Camarillo, California 93012 (US). **ELLISON, Murielle Marie** [US/US]; 645 Camino Manzanas, Thousand Oaks, California 91360 (US). **HAMBURGER, Agnes Eva** [US/US]; 3885 Calle Alta Vista, Thousand Oaks, California 91320 (US). **HECHT, Randy Ira** [US/US]; 2569 Piccadilly Circle, Thousand Oaks, California 91362 (US). **LI, Yue-Sheng** [US/US]; 3025 Shadow Hill Circle, Thousand Oaks, California 91360 (US). **MICHAELS, Mark Leo** [US/US]; 5007 Texhoma Avenue, Encino, California 91316 (US). **SUN, Jeonghoon** [KR/US]; 4340 Camino De La Rosa, Thousand Oaks, California 91320 (US). **XU, Jing** [CN/US]; 1677 Glider Court, Thousand Oaks, California 91320 (US).

(74) Agent: **LAMERDIN, John A.**; Patent Operations, M/S 28-2-C, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:


— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

[Continued on next page]

(54) Title: FGF21 MUTANTS AND USES THEREOF

FIG. 36



(57) Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.

WO 2010/129503 A1

— *with sequence listing part of description (Rule 5.2(a))*